FECAL MICROBIOTA COMPOSITION FOR USE IN REDUCING TREATMENT-INDUCED INFLAMMATION Russian patent published in 2024 - IPC A61K35/38 A61K35/74 A61P1/00 A61P43/00 

FIELD: medicine.

SUBSTANCE: group of inventions relates to the use of a faecal microbiota composition for preventing and/or reducing treatment-induced inflammation in a patient with cancer and/or haematological disease and a method for preventing and/or reducing treatment-induced inflammation in a patient suffering cancer and/or haematological disease. Use of the faecal microbiota composition for preventing and/or reducing treatment-induced inflammation in a patient suffering cancer and/or haematological disease, wherein the faecal microbiota composition is prepared by a method comprising the following steps: (i) collecting a stool sample and placing it in anaerobic conditions for maximum of 5 minutes after collection; (ii) still under anaerobic conditions, mixing the sample with an aqueous saline solution comprising a cryoprotectant and/or bulking agent; and (iii) filtering the diluted sample, wherein the treatment-induced inflammation is caused by anti-cancer therapy and/or haemopoietic stem cell transplantation (HSCT), where the proportion of some or all of following 15 genera increases compared to the pre-faecal FMT microbiota transfer level: Blautia, Faecalibacterium, Alistipes, Eubacterium, Bifidobacterium, Ruminococcus, Clostridium, Coprococcus, Odoribacter, Roseburia, Holdemanella, Anaerostipes, Oscillibacter, Subdoligranulum and Butyrivibrio, and wherein faecal microbiota transfer (FMT) with said faecal microbiota composition leads to a decrease in the level of neopterin in the intestine and/or a decrease in the level of serum CRP and/or serum ferritin. Method of preventing and/or reducing treatment-induced inflammation in a patient suffering cancer and/or haematological disease, comprising administering a faecal microbiota composition, wherein the faecal microbiota composition is obtained using the method described above.

EFFECT: group of inventions described above enables to obtain a faecal microbiota composition using a reliable and reproducible process which complies with good manufacturing practice (GMP) and meets modern pharmaceutical requirements in terms of safety and efficacy, the obtained composition has improved and optimal anti-inflammatory ability.

14 cl, 9 dwg, 14 tbl, 3 ex